G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer
Clinical trial NCT03455829 · COMPLETED
Trial details
- NCT number
- NCT03455829
- Sponsor
- G1 Therapeutics, Inc.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-03-29
- Primary completion
- 2021-12-14
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.